



May 9, 2024

**BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Ltd.,**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

**Dear Sir/Madam,**

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulation').**

We are pleased to enclose a Press Release as regards, appointment of Mr. Jeffrey Kindler and Mr. Alfonso "Chito" Zulueta as Independent Directors of the Company.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS - 11973)**

**Encl: a/a**



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## Jeffrey Kindler and Alfonso Zulueta Join Lupin Board as Independent Directors

**Mumbai, Naples, May 09, 2024:** Pharma major Lupin Limited (Lupin) announced the appointment of Mr. Jeffrey Kindler and Mr. Alfonso “Chito” Zulueta as Independent Directors to its Board.

Mr. Kindler is an experienced healthcare executive, investor and advisor. He brings over four decades of business experience and has held leadership positions at some of the world’s most recognized companies including Pfizer, where he served as Chairman & Chief Executive Officer, as well as McDonald's Corporation and General Electric Company. Before that, he was a partner at law firm Williams & Connolly.

Mr. Kindler is currently CEO of Centrexion Therapeutics, a privately held biotechnology company, Senior Advisor to Blackstone, Operating Partner at ARTIS Ventures and Global Chair of GLG Institute. In addition, Mr. Kindler is member of the board of directors of a number of companies, including Precigen Inc., Perrigo Pharmaceuticals and Terns Pharmaceuticals. Mr. Kindler holds a Bachelor of Arts degree (Summa cum Laude) from Tufts University, USA and a Juris Doctor degree (Magna cum Laude) from Harvard Law School, USA.

Mr. Zulueta spent over three decades in various roles of increasing responsibility with Eli Lilly and Company, including as Vice President of Global Marketing, President of Global Oncology and Critical Care Products and most recently, as President of International responsible for all geographies outside the United States and Canada. He also served as a corporate officer and member of Eli Lilly and Company’s Executive Committee. Mr. Zulueta previously served as member of the board of the European Federation of Pharmaceutical Industries and Associations and the U.S.-Japan Business Council.

Mr. Zulueta currently serves as Non-Executive Chairman of the board of directors of Interpharma Investments Limited, the holding company of Zuellig Pharma, one of the largest healthcare services groups in Asia. He is also president/CEO of CZ Ventures, a company focused on start-up investments, and member of the board of directors at Glooko, CTS Corporation, and Bridge PayDay Solutions. Mr. Zulueta holds an Economics undergraduate degree from De La Salle University, Manila, where he was conferred the 2023 Outstanding Alumnus Award, and MBA degree in Marketing/Finance from the University of Virginia, Darden School of Business, USA.

Commenting on the appointments, **Vinita Gupta, Chief Executive Officer, Lupin** said, "We are delighted to welcome Jeff and Chito to our board. Their extensive experience in building healthcare institutions, strategic perspectives of our industry and deep understanding of the evolving global pharmaceutical landscape, will enable us to advance our growth plans in the years to come."



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

**About Lupin**

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.8% of its revenue in research and development in FY24.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on

LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

Twitter: <https://twitter.com/LupinGlobal>

**For further information or queries please contact –**

**Heena Dhedhi**

Deputy General Manager – Corporate Communications

Email: [heenadhedhi@lupin.com](mailto:heenadhedhi@lupin.com)